By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juventas Therapeutics, Inc. 

10265 Carnegie Avenue

Cleveland  Ohio  44106  U.S.A.
Phone: 216-445-0830 Fax: 216-445-6514



Company News
Juventas Therapeutics, Inc. Enrolls First Patient In Phase 2 Gene Therapy Clinical Trial For Treatment Of Advanced Peripheral Artery Disease 2/4/2016 11:05:24 AM
Juventas Therapeutics, Inc. Granted FDA Fast Track Designation And Phase 2b Protocol Allowance For Novel Heart Failure Gene Therapy 6/16/2015 6:18:59 AM
Juventas Therapeutics, Inc. Presents New 12-Month Data Demonstrating Single Administration Of JVS-100 Improves Cardiac And Clinical Status In Patients With Severe Ischemic Heart Failure One Year After Treatment 5/26/2015 6:26:35 AM
Juventas Therapeutics, Inc. Adds $13.5 Million In New Financing And Expands Board Of Directors 5/12/2015 7:44:46 AM
Juventas Therapeutics, Inc. Presents Phase 2 Data At American Heart Association Scientific Sessions That Shows JVS-100 Is Safe, Potentially Effective In Patients With Critical Limb Ischemia 11/18/2014 10:27:32 AM
Juventas Therapeutics, Inc. Phase 2 Clinical Study Results To Be Presented At 2014 American Heart Association Scientific Sessions 11/12/2014 9:14:09 AM
Juventas Therapeutics, Inc. Strengthens Management Team With New Senior Vice President Of Finance And Operations 10/28/2014 8:54:40 AM
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014 8:03:56 AM
Juventas Therapeutics, Inc. Strengthens Leadership Team By Adding Two Industry Veterans 7/24/2014 9:16:36 AM
Juventas Therapeutics, Inc. To Present At The JMP Securities 2014 Healthcare Conference On June 24 6/23/2014 8:28:11 AM